A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer

Abstract

Accumulating studies explored the clinicopathologic and prognostic value of programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC), but the results were controversial. We therefore conducted a meta-analysis to evaluate the predictive role of PD-L1 in NSCLC patients. We systematically collected relevant studies from PubMed, Embase, Web of Science and China National Knowledge Infrastructure. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS), and odd ratios (ORs) with 95% CIs for clinicopathologic factors were calculated. A total of 15 studies involving 3605 patients were included in this meta-analysis. The results showed no prognostic role of PD-L1 in the whole patients (HR=1.60, 95% CI: 0.88–2.89, P=0.123). Subgroup analysis showed that PD-L1 was associated with decreased OS in Asian patients (HR=2.00, 95% CI: 1.55–2.57, P<0.001). Among all the clinicopathologic factors, PD-L1 overexpression was significantly in relevance with poor tumor cell differentiation (HR=1.84, 95% CI: 1.49–2.28, P<0.001), late stage (HR=1.21, 95% CI: 1.02–1.43, P=0.026) and anaplastic lymphoma kinase (ALK) translocation (HR=2.63, 95% CI: 1.08–6.40, P=0.034), but not with other factors. In conclusion, our meta-analysis demonstrated that PD-L1 has a prognostic role in Asian patients with NSCLC.

Keywords

meta-analysis / overall survival / clinicopathologic factors / non-small cell lung cancer

References

[1] TorreLA, BrayF, SiegelRL, et al. . Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108 PMID: 25651787

[2] SiegelR, DeSantisC, VirgoK, et al. . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin, 2012, 62(4): 220-241 PMID: 22700443

[3] HanahanD, WeinbergRA. Hallmarks of cancer: the next generation. Cell, 2011, 144(5): 646-674 PMID: 21376230

[4] DongH, ChenL. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med., 2003, 81(5): 281-287 PMID: 12721664

[5] DongH, ZhuG, TamadaK, et al. . B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 1999, 5: 1365-1369 PMID: 10581077

[6] ChenL. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol, 2004, 4: 336-347 PMID: 15122199

[7] LinZ, XuY, ZhangY, et al. . The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. Oncotarget, 2016

[8] DroeserRA, HirtC, ViehlCT, et al. . Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer, 2013, 49(9): 2233-2242 PMID: 23478000

[9] ShiSJ, WangLJ, WangGD, et al. . B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One, 2013, 8(10): e76012 PMID: 24124529 PMCID: 3790819

[10] LiangM, LiJ, WangD, et al. . T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China's Heilongjiang province. Tumour Biol, 2014, 35(1): 55-60 PMID: 23873101

[11] ChenYB, MuCY, HuangJA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori, 2012, 98(6): 751-755 PMID: 23389362

[12] VelchetiV, SchalperKA, CarvajalDE, et al. . Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest, 2014, 94(1): 107-116 PMID: 24217091

[13] YangCY, LinMW, ChangYL, et al. . Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer, 2014, 50(7): 1361-1369 PMID: 24548766

[14] TierneyJF, StewartLA, GhersiD, et al. . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007, 8: 16 PMID: 17555582 PMCID: 1920534

[15] SteelsE, PaesmansM, BerghmansT, et al. . Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J, 2001, 18(4): 705-719 PMID: 11716177

[16] DinnesJ, DeeksJ, KirbyJ, et al. . A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess, 2005, 9(12): 1-113

[17] PatsopoulosNA, EvangelouE, IoannidisJP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol, 2008, 37(5): 1148-1157 PMID: 18424475

[18] BeggCB, MazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994, 50(4): 1088-1101 PMID: 7786990

[19] KonishiJ, YamazakiK, AzumaM, et al. . B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res, 2004, 10(15): 5094-5100 PMID: 15297412

[20] MuCY, HuangJA, ChenY, et al. . High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol, 2011, 28(3): 682-688 PMID: 20373055

[21] ChenYY, WangLB, ZhuHL, et al. . Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J, 2013, 28(3): 147-151 PMID: 24074616

[22] ZhangY, WangL, LiY, et al. . Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther, 2014, 7: 567-73 PMID: 24748806 PMCID: 3990506

[23] AzumaK, OtaK, KawaharaA, et al. . Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol, 2014, 25(10): 1935-1940 PMID: 25009014

[24] CooperWA, TranT, VilainRE, et al. . PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 2015, 89(2): 181-188 PMID: 26024796

[25] MaoY, LiW, ChenK, et al. . B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget, 2015, 6(5): 3452-3461 PMID: 25609202

[26] KimMY, KohJ, KimS, et al. . Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer, 2015, 88(1): 24-33 PMID: 25662388

[27] MaW, LuoDZ, ChenY. Expression and clinical significance of PD-L1 and PD-1 in non-small cell lung cancer. J Prac Med, 2011, 27(9): 1551-1554

[28] SharmaS. Research on PD-L1 expression and significance in patients with NSCLC, 2014

[29] SchmidtLH, KummelA, GorlichD, et al. . PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One, 2015, 10(8): e0136023 PMID: 26313362 PMCID: 4552388

[30] KohJ, GoH, KeamB, et al. . Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status, 2015, 28(9): 1154-1166

[31] PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12(4): 252-264 PMID: 22437870 PMCID: 4856023

[32] SanmamedMF, ChenL. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J, 2014, 20(4): 256-261 PMID: 25098285 PMCID: 4455021

[33] TsushimaF, YaoS, ShinT, et al. . Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood, 2007, 110(1): 180-185 PMID: 17289811 PMCID: 1896111

[34] DongH, StromeSE, SalomaoDR, et al. . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 2002, 8(8): 793-800 PMID: 12091876

[35] BlankC, MackensenA. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother, 2007, 56(5): 739-745 PMID: 17195077

[36] JinHT, AhmedR, OkazakiT. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol, 2011, 350: 17-37 PMID: 21061197

[37] TaubeJM, AndersRA, YoungGD, et al. . Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med, 2012, 4(127): 127ra37 PMID: 22461641 PMCID: 3568523

[38] SprangerS, SpaapenRM, ZhaY, et al. . Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med, 2013, 5(200): 200ra116 PMID: 23986400 PMCID: 4136707

[39] Homet MorenoB, RibasA. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer, 2015, 112(9): 1421-1427 PMID: 25856776 PMCID: 4453674

[40] LipsonEJ, SharfmanWH, DrakeCG, et al. . Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res, 2013, 19(2): 462-468 PMID: 23169436

[41] PowlesT, EderJP, FineGD, et al. . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014, 515(7528): 558-562 PMID: 25428503

[42] HerbstRS, SoriaJC, KowanetzM, et al. . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515(7528): 563-567 PMID: 25428504 PMCID: 4836193

[43] TaubeJM. Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology, 2014, 3(11): e963413 PMID: 25914862 PMCID: 4292419

[44] PatelSP, KurzrockR. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther, 2015, 14(4): 847-856 PMID: 25695955

[45] ParsaAT, WaldronJS, PannerA, et al. . Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med, 2007, 13(1): 84-88 PMID: 17159987

[46] SongM, ChenD, LuB, et al. . PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One, 2013, 8(6): e65821 PMID: 23785454 PMCID: 3681867

[47] XuC, FillmoreCM, KoyamaS, et al. . Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell, 2014, 25(5): 590-604 PMID: 24794706 PMCID: 4112370

[48] AkbayEA, KoyamaS, CarreteroJ, et al. . Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov, 2013, 3(12): 1355-1363 PMID: 24078774

[49] MellmanI, CoukosG, DranoffG. Cancer immunotherapy comes of age. Nature, 2011, 480(7378): 480-489 PMID: 22193102 PMCID: 3967235

[50] KirkwoodJM, ButterfieldLH, TarhiniAA, et al. . Immunotherapy of cancer in 2012. CA Cancer J Clin, 2012, 62(5): 309-335 PMID: 22576456 PMCID: 3445708

[51] GandiniS, MassiD, MandalaM. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol, 2016, 100: 88-98 PMID: 26895815

[52] JiaM, FengW, KangS, et al. . Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. J Thorac Dis, 2015, 7: 455-461 PMID: 25922725 PMCID: 4387409

[53] PanZK, YeF, WuX, et al. . Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis, 2015, 7(3): 462-470 PMID: 25922726 PMCID: 4387432

[54] ZhouZJ, ZhanP, SongY. PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res, 2015, 4(2): 203-208 PMID: 25870804 PMCID: 4384212

[55] WangA, WangHY, LiuY, et al. . The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol, 2015, 41(4): 450-456 PMID: 25682184